JP Morgan Maintains Neutral on Legend Biotech, Lowers Price Target to $33

Benzinga Newsdesk www.benzinga.com Negative 83.8%

Neg 83.8% Neu 0% Pos 0%

JP Morgan analyst Jessica Fye maintains Legend Biotech (NASDAQ:LEGN) with a Neutral and lowers the price target from $35 to $33.